Lung Cancer Marker Antibody (MOC-52), Novus Biologicals™

Mouse Monoclonal Antibody

Catalog Number	Mfr. No.	Quantity
NBP24527700	Novus Biologicals NBP2452770.02MG	0.02 mg
NBP24527701	Novus Biologicals NBP2452770.1MG	0.1 mg
NBP24527702	Novus Biologicals NBP2452770.2MG	0.2 mg

Description

Ensure accurate, reproducible results in Immunocytochemistry, Immunofluorescence

Lung Cancer Marker MOC-52 Monoclonal specifically detects Lung Cancer Marker MOC-52 in Human samples. It is validated for Immunocytochemistry/Immunofluorescence, Immunofluorescence, Immunocytochemistry.

Specifications

• Antigen: Lung Cancer Marker MOC-52
• Concentration: 0.2 mg/mL
• Applications: SDS-Page, Immunofluorescence, Immunocytochemistry
• Conjugate: Unconjugated
• Host Species: Mouse
• Research Discipline: Cancer, Neuronal Cell Markers, Neuronal Stem Cell Markers, Stem Cell Markers
• Formulation: 10mM PBS and 0.05% BSA with 0.05% Sodium Azide
• Immunogen: Lung Cancer-associated antigen isolated from small cell lung carcinoma-derived cell line.
• Primary or Secondary: Primary
• Content And Storage: Store at 4C.
• Molecular Weight of Antigen: 145 kDa

• Clone: MOC-52
• Dilution: SDS-Page, Immunofluorescence 0.5 - 1.0 ug/ml, Immunocytochemistry 0.5 - 1.0 ug/ml
• Classification: Monoclonal
• Form: Purified
• Regulatory Status: RUO
• Target Species: Human
• Gene ID (Entrez): 100133941
• Isotype: IgG1 κ
• Purification Method: Protein A or G purified
• Test Specificity: This MAb reacts with a membrane-associated protein present in normal and malignant neuroendocrine tissues including small cell lung cancer (SCLC). It stains neural and a variable number of endocrine tissues and in the lung it reacts preferentially with SCLC and carcinoids. Its epitope is destroyed during formalin fixation. This antibody was categorized during the First International Workshop on Small Cell Lung Cancer Antigens held in London in April 1987. There are two major types of Lung Carcinoma: non-small cell, which accounts for 80% of all cases; and small cell, which accounts for roughly 20% of all lung cancers reported. The lung continues to be a customary place for cancer migration from tumors elsewhere in the body. Treatment depends on the specific cell type of the cancer, level of progression and status of the individual patient.

For Research Use Only